

NUTRA PHARMA CORP  
Form 8-K  
March 07, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) February 23, 2018**

**NUTRA PHARMA CORP.**

**(Exact name of registrant as specified in its charter)**

**California**  
**(State or other jurisdiction  
of incorporation)**

**000-32141**  
**(Commission File Number)**

**91-2021600**  
**(IRS Employer  
Identification No.)**

**12538 West Atlantic Blvd**  
**Coral Springs, Florida**  
**(Address of principal executive offices)**

**33071**  
**(Zip Code)**

**Registrant's telephone number, including area code: (954) 509-0911**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Nutra Pharma Corp. is referred to herein as we, our, or us .

## **Section 1 Registrant s Business and Operations**

### **Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers**

#### *Resignation of Dan Oran as our Director*

On February 23, 2018, Dan Oran, our Director since July 21, 2016, resigned as a Director of our Board of Directors. Mr. Oran s resignation as a Director was not regarding any matter pertaining to our operations, policies or practices.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 7, 2018

NUTRA PHARMA CORP.

By: /s/ Rik J. Deitsch

Name: Rik J. Deitsch

Title: Chief Executive Officer